• Fulfilling

    Potential™

    With the Science of Enzymes

  • Fulfilling

    Potential™

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis

Feb 23, 2021

Newton, M.A. – February, 23 2021 – Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced  publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee recommending the use of RELiZORB® (immobilized lipase cartridge), a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase.

Read More

Alcresta Therapeutics Appoints Alan Muney, MD to Board Of Directors

Dec 07, 2020

NEWTON, MA, December 7, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors. Dr. Muney is currently a senior healthcare advisor for Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture Capital.

Read More

Alcresta Therapeutics’ RELiZORB® (immobilized lipase) cartridge shows long-term effectiveness in enterally fed patients with cystic fibrosis

Nov 11, 2020

NEWTON, MA, November 11, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the publication of a 12-month observational study in Journal of Pediatric Gastroenterology & Nutrition that evaluated the effectiveness of long-term RELiZORB® (iMMOBILIZED LIPASE) Cartridge use in enterally fed patients with cystic fibrosis.

Read More